Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes

References

• American Cancer Society. Key statistics for acute myeloid leukemia (AML). Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html. Accessed August 6, 2019.
   Google Scholar
• Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555–573. doi:10.1200/EDBK_199519
   PubMedGoogle Scholar
• Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649. doi:10.1200/JCO.2014.60.0890
   PubMed Web of Science ®Google Scholar
• Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin. 2017;33(3):519–527. doi:10.1080/03007995.2016.1267615
   PubMed Web of Science ®Google Scholar
• Halpern AB, Culakova E, Walter RB, Lyman GH. Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit. JAMA Oncol. 2017;3(3):374–381. doi:10.1001/jamaoncol.2016.4858
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.6112
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Mims AS. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: a new twist on an old cocktail. Best Pract Res Clin Haematol. 2019;32(2):127–133. doi:10.1016/j.beha.2019.05.005
   PubMed Web of Science ®Google Scholar
• Chen EC, Fathi AT, Brunner AM. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther. 2018;11:3425–3434. doi:10.2147/OTT.S141212
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246. doi:10.1182/blood-2013-12-540971
   PubMed Web of Science ®Google Scholar
• Talati C, Lancet JE. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Future Oncol. 2018;14(12):1147–1154. doi:10.2217/fon-2017-0603
   PubMed Web of Science ®Google Scholar
• Kolitz JE, Strickland SA, Cortes JE, et al. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020;61(3):631–640. doi:10.1080/10428194.2019.1688320
   PubMed Web of Science ®Google Scholar
• Villa KF, Ryan RJ, Chiarella M, Louie AC. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia. J Med Econ. 2020;23(7):714–720. doi:10.1080/13696998.2020.1744613
   PubMed Web of Science ®Google Scholar
• Premier Applied Sciences®. Premier Inc. Premier Healthcare Database: data that informs and performs. Available from: https://learn.premierinc.com/white-papers/premier-healthcare-database-whitepaper. Accessed May 12, 2021.
   Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923–932. doi:10.1182/bloodadvances.2018016121
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi:10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar
• Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–144. doi:10.1146/annurev.publhealth.20.1.125
   PubMed Web of Science ®Google Scholar
• Engel-Nitz NM, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res. 2011;3:233–245. doi:10.2147/CMR.S21033
   PubMedGoogle Scholar
• DaCosta Byfield S, Nash Smyth E, Mytelka D, Bowman L, Teitelbaum A. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379–1386. doi:10.3111/13696998.2013.848208
   PubMedGoogle Scholar
• Bell JA, Galaznik A, Farrelly E, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27–33. doi:10.1016/j.leukres.2018.06.010
   PubMed Web of Science ®Google Scholar
• Meyer N, Hao Y, Landsman-Blumberg P, Johnson W, Juneau P, Willemann Rogerio J. Health care costs and utilization of a large insured female population with advanced or metastatic breast cancer by receipt of HER2-targeted agents. Comp Eff Res. 2015;5:21–34. doi:10.2147/CER.S62090
   Google Scholar
• Weichle T, Hynes DM, Durazo-Arvizu R, Tarlov E, Zhang Q. Impact of alternative approaches to assess outlying and influential observations on health care costs. Springerplus. 2013;2:614. doi:10.1186/2193-1801-2-614
   PubMed Web of Science ®Google Scholar
• Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005;6(1):93–109. doi:10.1093/biostatistics/kxh020
   PubMed Web of Science ®Google Scholar
• Li Z, Mahendra G. Using “recycled predictions” for computing marginal effects. SAS Global Forum 2010, Statistics and Data Analysis. Paper 272-2010. Available from: https://support.sas.com/resources/papers/proceedings10/272-2010.pdf. Accessed May 5, 2021.
   Google Scholar
• Vyxeos dosing and administration information. Available from: https://vyxeospro.com/files/Vyxeos-Dosing-Brochure.pdf. Accessed April 6, 2020.
   Google Scholar
• UpToDate®. Liposomal daunorubicin and cytarabine: drug information. Available from: https://www.uptodate.com/contents/liposomal-daunorubicin-and-cytarabine-drug-information?search=liposomal%20daunorubicin-cytarabine&source=panel_search_result&selectedTitle=1~7&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed April 7, 2020.
   Google Scholar
• Krauss AC, Gao X, Li L, et al. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019;25(9):2685–2690. doi:10.1158/1078-0432.CCR-18-2990
   PubMed Web of Science ®Google Scholar
• Fedele PL, Avery S, Patil S, Spencer A, Haas M, Wei A. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Intern Med J. 2014;44(8):757–763. doi:10.1111/imj.12478
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Shankaran V, Walter RB. Trends in clinical benefits and costs of novel therapeutics in AML: at what price does progress come? Curr Hematol Malig Rep. 2019;14(3):171–178. doi:10.1007/s11899-019-00510-2
   PubMed Web of Science ®Google Scholar
• Jensen IS, Wu E, Sacks NC, Cyr PL, Chung KC. Budget impact analysis of using daunorubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits. 2018;11(7):380–386.
   PubMed Web of Science ®Google Scholar
• Urbino I, Secreto C, Olivi M, et al. Evolving therapeutic approaches for older patients with acute myeloid leukemia in 2021. Cancers (Basel). 2021;13(20):5075. doi:10.3390/cancers13205075
   PubMed Web of Science ®Google Scholar
• Saxena K, Konopleva M. New treatment options for older patients with acute myeloid leukemia. Curr Treat Options Oncol. 2021;22(5):39. doi:10.1007/s11864-021-00841-4
   PubMed Web of Science ®Google Scholar
• Chiche E, Rahmé R, Bertoli S, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5(1):176–184. doi:10.1182/bloodadvances.2020003159
   PubMed Web of Science ®Google Scholar
• Guolo F, Fianchi L, Minetto P, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10(10):96. doi:10.1038/s41408-020-00361-8
   PubMed Web of Science ®Google Scholar
• Rautenberg C, Stolzel F, Rollig C, et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11(10):164. doi:10.1038/s41408-021-00558-5
   PubMed Web of Science ®Google Scholar